GlaxoSmithKline’s new chief executive, Emma Walmsley, has laid out plans to cut nearly one in seven of the pharma group’s clinical drug development programmes as part of a shakeup of the business. They included 13 in clinical development, including treatments for hepatitis C, psoriasis, cancer and rheumatoid arthritis, and about 20 in preclinical development. Ninety-four clinical drug development programmes were in progress at Britain’s biggest pharmaceuticals firm. GSK did not release the number of its preclinical programmes, but its rare diseases unit was also under review. Walmsley stressed the research-and-development budget would not be cut and that the money saved would be spent on other areas.

Source: The Guardian July 26, 2017 17:36 UTC